Androgen deprivation as a strategy for prostate cancer chemoprevention.

Androgens are required for the normal development and function of the prostate gland. Prostate cancer and benign prostatic hyperplasia are common in men and develop in an environment of continuous androgen exposure. The utility of androgen deprivation as a treatment for advanced prostate cancer was first demonstrated in 1941 (1), and many new classes of drugs that interfere with androgen production and function have been introduced in recent years. These agents are effective in treating prostate cancer and benign prostatic hyperplasia and may have an important role in chemoprevention. Since 1991, prostate cancer has been the most common noncutaneous cancer and the second leading cause of cancer-related death in men. The major difficulty in treating prostate cancer is the limitation of current tools to accurately predict the behavior of a given tumor. Although many prostate cancers are clinically insignificant and will have an indolent course, others will result in considerable morbidity and mortality. The major dilemma with regard to prostate cancer is determining what men to treat and who would be better served by expectant management (2). Previous efforts (3) have concentrated on treating invasive cancer, often in advanced stages. Other work (4,5) suggests that an evolving multistep molecular and cellular process, known as carcinogenesis, begins years before invasive cancer is detected. Chemoprevention refers to prevention of cancer or reduction of risk in susceptible individuals by administration of natural or synthetic drugs with little or no toxicity that suppress, delay, or reverse carcinogenesis (6,7). Chemoprevention is most effective in the early stages of cancer formation when reversibility may be feasible. In prostatic carcinoma, the time from tumor initiation and progression to invasive carcinoma often begins in men in the fourth and fifth decades of life and extends across decades, allowing sufficient time to halt or to reverse carcinogenesis (8,9).

[1]  P. Walsh.  The definition and preoperative prediction of clinically insignificant prostate cancer. , 1996, The Journal of urology.

[2]  N. Voravud.  Chemoprevention of head and neck cancer. , 1996, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[3]  J. Rice,et al.  Familial aspects of prostate cancer: a case control study. , 1995, The Journal of urology.

[4]  J. Trachtenberg,et al.  Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. , 1995, The Journal of urology.

[5]  D. Bostwick,et al.  The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. , 1995, The Journal of urology.

[6]  D. Bostwick,et al.  Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. , 1995, The Journal of urology.

[7]  J. Crowley,et al.  Design of the Prostate Cancer Prevention Trial (PCPT). , 1995, Controlled clinical trials.

[8]  David G. Bostwick,et al.  High grade prostatic intraepithelial neoplasia. The most likely precursor of prostate cancer , 1995 .

[9]  D. Alberts,et al.  An overview of clinical cancer chemoprevention studies with emphasis on positive phase III studies. , 1995, The Journal of nutrition.

[10]  J. Oesterling,et al.  Benign prostatic hyperplasia. Medical and minimally invasive treatment options. , 1995, The New England journal of medicine.

[11]  B. Kramer,et al.  The potential for hormonal prevention trials , 1994, Cancer.

[12]  W. Catalona,et al.  Management of cancer of the prostate. , 1994, The New England journal of medicine.

[13]  P. Cangh,et al.  Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer , 1994, Clinical endocrinology.

[14]  D. Bostwick,et al.  Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. , 1994, Cancer research.

[15]  D. Bostwick,et al.  Decrease of prostatic intraepithelialneoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy , 1994 .

[16]  V. Steele,et al.  Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. , 1994, Cancer research.

[17]  S. Lippman,et al.  Second international cancer chemoprevention conference. , 1994, Cancer research.

[18]  T. Beaty,et al.  Hereditary prostate cancer: epidemiologic and clinical features. , 1993, The Journal of urology.

[19]  G. Haas,et al.  The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. , 1993, The Journal of urology.

[20]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.

[21]  J. Simard,et al.  Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first‐line therapy , 1993, Cancer.

[22]  M. Soloway,et al.  Antiandrogenic agents as monotherapy in advanced prostatic carcinoma , 1993, Cancer.

[23]  S. Lippman,et al.  Regression of oral leukoplakia with alpha-tocopherol: a community clinical oncology program chemoprevention study. , 1993, Journal of the National Cancer Institute.

[24]  H. Garewal,et al.  Biological monitoring of cancer chemoprevention , 1992, Journal of surgical oncology.

[25]  D. Bostwick,et al.  The association of benign prostatic hyperplasia and cancer of the prostate , 1992, Cancer.

[26]  G. Goodman.  The clinical evaluation of cancer chemoprevention agents: defining and contrasting phase I, II, and III objectives. , 1992, Cancer research.

[27]  J. Bordas,et al.  Effects of long-term sulindac therapy on colonic polyposis. , 1991, Annals of internal medicine.

[28]  M. Spitz,et al.  Familial patterns of prostate cancer: a case-control analysis. , 1991, The Journal of urology.

[29]  P. Vielh,et al.  Sulindac causes regression of rectal polyps in familial adenomatous polyposis. , 1991, Gastroenterology.

[30]  M. Soloway,et al.  Pathologic changes associated with androgen deprivation therapy for prostate cancer , 1991, Cancer.

[31]  P. Lange,et al.  Significance of prostatic intraepithelial neoplasia on prostate needle biopsy. , 1991, Urology.

[32]  L J Peters,et al.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. , 1990, The New England journal of medicine.

[33]  F. Meyskens,et al.  Coming of age--the chemoprevention of cancer. , 1990, The New England journal of medicine.

[34]  N. Kyprianou,et al.  Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. , 1990, Cancer research.

[35]  S. Piantadosi,et al.  Clinical evidence for and implications of the multistep development of prostate cancer. , 1990, The Journal of urology.

[36]  M. Keating,et al.  Long-term experience with flutamide in patients with prostatic carcinoma. , 1989, Urology.

[37]  V. Serretta,et al.  Antiandrogens alone or in combination for treatment of prostate cancer: the European experience. , 1989, Urology.

[38]  F. Mostofi,et al.  Large acinar atypical hyperplasia and carcinoma of the prostate , 1988, Cancer.

[39]  N. Kyprianou,et al.  Activation of programmed cell death in the rat ventral prostate after castration. , 1988, Endocrinology.

[40]  W. Waddell,et al.  Sulindac for polyposis of the colon , 1983, Journal of surgical oncology.

[41]  G. Peck.  Chemoprevention of Cancer with Retinoids. , 1981, Gynecologic oncology.

[42]  M. Sporn,et al.  Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). , 1976, Federation proceedings.

[43]  R. E. Peterson,et al.  Steroid 5α-Reductase Deficiency in Man: An Inherited Form of Male Pseudohermaphroditism , 1974, Science.

[44]  J. D. Wilson,et al.  Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. , 1974, The New England journal of medicine.

[45]  J. D. Fergusson,et al.  Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. , 1973, British journal of urology.

[46]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[47]  J. Oesterling,et al.  The effect of finasteride on prostate specific antigen: review of available data. , 1996, The Journal of urology.

[48]  D. Bostwick,et al.  Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials , 1996, Journal of cellular biochemistry. Supplement.

[49]  V. Steele,et al.  Approaches to the development and marketing approval of drugs that prevent cancer. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[50]  G. Wilding.  Endocrine control of prostate cancer. , 1995, Cancer surveys.

[51]  P. Stone,et al.  Management of cancer of the prostate. , 1995, The New England journal of medicine.

[52]  S. Lippman,et al.  Cancer chemoprevention. , 1995, Journal of the National Cancer Institute. Monographs.

[53]  B. Kramer,et al.  Chemoprevention , 2004 .

[54]  V. Steele,et al.  Clinical development plan: Proscar. , 1994, Journal of cellular biochemistry. Supplement.

[55]  A. Kaisary,et al.  Current clinical studies with a new nonsteroidal antiandrogen, casodex , 1994, The Prostate. Supplement.

[56]  D. Bostwick,et al.  Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. , 1994, Urology.

[57]  Bostwick Dg.  Target populations and strategies for chemoprevention trials of prostate cancer. , 1994 .

[58]  Kaisary Av.  Current clinical studies with a new nonsteroidal antiandrogen, Casodex. , 1994 .

[59]  P. Engstrom,et al.  Chemoprevention of cancer. , 1994, Current problems in cancer.

[60]  D. Bostwick.  Target populations and strategies for chemoprevention trials of prostate cancer. , 1994, Journal of cellular biochemistry. Supplement.

[61]  V. Steele,et al.  Introductory remarks: Development of chemopreventive agents for prostate cancer , 1992, Journal of cellular biochemistry. Supplement.

[62]  G J Gormley,et al.  Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors. , 1992, Journal of cellular biochemistry. Supplement.

[63]  J. Isaacs,et al.  Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657. , 1992, The Prostate.

[64]  C. Vicentini,et al.  Antiandrogens and 5-alpha reductase inhibition of the proliferation rate in PC3 and DU145 human prostatic cancer cell lines , 1992 .

[65]  J. Isaacs,et al.  Response of rat and human prostatic cancers to the novel 5α‐reductase inhibitor, SK&F 105657 , 1992 .

[66]  G. Gormley,et al.  Chemoprevention strategies for prostate cancer: The role of 5α‐reductase inhibitors , 1992 .

[67]  S. Lippman,et al.  Chemoprevention of head and neck cancer , 2010 .

[68]  Leuprolide versus diethylstilbestrol for metastatic prostate cancer. , 1984, The New England journal of medicine.